135 related articles for article (PubMed ID: 340032)
21. Phase II study with amsacrines (m-AMSA and m-AMSA lactate) in refractory lymphomas.
Bajetta E; Buzzoni R; Viviani S; Villani F; Piotti P; Gasparini G; Bonadonna G
Cancer Treat Rep; 1985 Sep; 69(9):965-9. PubMed ID: 3839714
[TBL] [Abstract][Full Text] [Related]
22. cis-dichlorodiammineplatinum(II) with and without ICRF-159 in non-Hodgkin's lymphoma.
Corder MP; Wiesenfeld M; Maguire LC; Leimert JT; Panther SK
Cancer Treat Rep; 1980; 64(2-3):301-4. PubMed ID: 7190869
[TBL] [Abstract][Full Text] [Related]
23. Piperazinedione in metastatic renal carcinoma.
Pasmantier MW; Coleman M; Kennedy BJ; Eagan R; Carolla R; Weiss R; Leone L; Silver RT
Cancer Treat Rep; 1977 Dec; 61(9):1731-2. PubMed ID: 340039
[No Abstract] [Full Text] [Related]
24. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.
Dowlati A; Lazarus HM; Hartman P; Jacobberger JW; Whitacre C; Gerson SL; Ksenich P; Cooper BW; Frisa PS; Gottlieb M; Murgo AJ; Remick SC
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5929-35. PubMed ID: 14676117
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of VP-16-213 in malignant lymphoma and melanoma.
Cecil JW; Quagliana JM; Coltman CA; Al-Sarraf M; Thigpen T; Groppe CW
Cancer Treat Rep; 1978 May; 62(5):801-3. PubMed ID: 657164
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma.
Case DC; Hayes DM; Gerber M; Gams R; Ervin TJ; Dorsk BM
Cancer Res; 1990 Nov; 50(21):6833-5. PubMed ID: 2208149
[TBL] [Abstract][Full Text] [Related]
27. Innovative treatment strategies for non-Hodgkin's lymphoma and multiple myeloma.
Borden EC
Semin Oncol; 1994 Dec; 21(6 Suppl 14):14-22. PubMed ID: 7992095
[TBL] [Abstract][Full Text] [Related]
28. Treatment of recurrent lymphomas with vincristine, BCNU, doxorubicin, and prednisone (VBAP): a Southwest Oncology Group Study.
Weick JK; Jones SE; Haut A; Fisher R; Dixon D
Cancer Treat Rep; 1981; 65(7-8):611-4. PubMed ID: 6166373
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
[TBL] [Abstract][Full Text] [Related]
30. Salvage treatment of unfavorable non-Hodgkin's lymphoma with cisplatin, amsacrine, and mitoguazone: a Southwest Oncology Group Pilot Study.
Dana BW; Jones SE; Coltman C; Stuckey WJ
Cancer Treat Rep; 1986 Feb; 70(2):291-2. PubMed ID: 3753898
[TBL] [Abstract][Full Text] [Related]
31. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study.
Rosenthal S; Harris DT; Horton J; Glick JH
Cancer Treat Rep; 1980; 64(10-11):1115-7. PubMed ID: 7459897
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of ICRF-187 by 48-hour continuous infusion.
Koeller JM; Earhart RH; Davis HL
Cancer Treat Rep; 1981; 65(5-6):459-63. PubMed ID: 6786740
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of vinzolidine, an oral vinca alkaloid, in Hodgkin's disease and non-Hodgkin's lymphoma.
Takasugi BJ; Jones SE; Robertone AB
Cancer Treat Rep; 1984 Nov; 68(11):1399-401. PubMed ID: 6498855
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B.
Cavalli F; Jungi WF; Nissen NI; Pajak TF; Coleman M; Holland JF
Cancer; 1981 Nov; 48(9):1927-30. PubMed ID: 7197582
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary. A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; Arseneau JC; Homesley HD
Am J Clin Oncol; 1984 Jun; 7(3):261-3. PubMed ID: 6547268
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of piperazinedione in metastatic sarcoma.
Presant CA; Bartolucci AA
Am J Clin Oncol; 1982 Apr; 5(2):185-7. PubMed ID: 7046413
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of adriamycin and bleomycin in patients with multiple myeloma.
Bennett JM; Silber R; Ezdinli E; Levitt M; Oken M; Bakemeier RF; Bailar JC; Carbone PP
Cancer Treat Rep; 1978 Sep; 62(9):1367-9. PubMed ID: 80275
[TBL] [Abstract][Full Text] [Related]
39. Gallium nitrate in malignant lymphoma: a Southwest Oncology Group study.
Weick JK; Stephens RL; Baker LH; Jones SE
Cancer Treat Rep; 1983 Sep; 67(9):823-5. PubMed ID: 6883359
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of piperazinedione (NCS 135758) in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
Thigpen JT; Blessing J; Homesley HD; Adcock LL
Am J Clin Oncol; 1983 Aug; 6(4):423-6. PubMed ID: 6688150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
